CIBINQO Drug Patent Profile

Which patents cover Cibinqo, and when can generic versions of Cibinqo launch?

Cibinqo is a drug marketed by Pfizer and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-five patent family members in forty-four countries.

The generic ingredient in CIBINQO is abrocitinib. Two suppliers are listed for this compound. Additional details are available on the abrocitinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Cibinqo

Cibinqo was eligible for patent challenges on January 14, 2026.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 14, 2036. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for CIBINQO

International Patents:	65
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	39
Clinical Trials:	2
Patent Applications:	406
Drug Prices:	Drug price information for CIBINQO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CIBINQO
What excipients (inactive ingredients) are in CIBINQO?	CIBINQO excipients list
DailyMed Link:	CIBINQO at DailyMed

See drug prices for CIBINQO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for CIBINQO

Constraining patent/regulatory exclusivity:

9,035,074

NDA:

213871

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for CIBINQO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Pfizer	Phase 2
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2
Innovaderm Research Inc.	Phase 4

See all CIBINQO clinical trials

Pharmacology for CIBINQO

Drug Class	Janus Kinase Inhibitor
Mechanism of Action	Janus Kinase Inhibitors P-Glycoprotein Inhibitors

Paragraph IV (Patent) Challenges for CIBINQO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CIBINQO	Tablets	abrocitinib	50 mg, 100 mg and 200 mg	213871	3	2026-01-14

US Patents and Regulatory Information for CIBINQO

CIBINQO is protected by three US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 9,035,074.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	CIBINQO	abrocitinib	TABLET;ORAL	213871-001	Jan 14, 2022		RX	Yes	No	9,549,929
Pfizer	CIBINQO	abrocitinib	TABLET;ORAL	213871-002	Jan 14, 2022		RX	Yes	No	9,035,074		Y	Y
Pfizer	CIBINQO	abrocitinib	TABLET;ORAL	213871-001	Jan 14, 2022		RX	Yes	No
Pfizer	CIBINQO	abrocitinib	TABLET;ORAL	213871-003	Jan 14, 2022		RX	Yes	Yes	9,545,405		Y	Y
Pfizer	CIBINQO	abrocitinib	TABLET;ORAL	213871-002	Jan 14, 2022		RX	Yes	No	9,545,405		Y	Y

EU/EMA Drug Approvals for CIBINQO

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pfizer Europe MA EEIG	Cibinqo	abrocitinib	EMEA/H/C/005452Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.	Authorised	no	no	no	2021-12-09

International Patents for CIBINQO

When does loss-of-exclusivity occur for CIBINQO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Costa Rica

Croatia

Cuba

Cyprus

Denmark

Dominican Republic

Eurasian Patent Organization

European Patent Office

Georgia, Republic of

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Moldova, Republic of

Montenegro

Morocco

Netherlands

New Zealand

Norway

Peru

Philippines

Poland

Portugal

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Turkey

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering CIBINQO around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	094857	DERIVADOS DE PIRROLO[2,3-D]PIRIMIDINA
Australia	2014220357	Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of Janus- related Kinases (JAK)
Brazil	112015019634	derivados de pirrolo[2,3-d]pirimidina como inibidores de janus kinase (jak)
Canada	2900703	DERIVES DE PYRROLO[2,3-D]PYRIMIDINE EN TANT QU'INHIBITEURS DE JANUS KINASES (JAK) (PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF JANUS- RELATED KINASES (JAK))
Chile	2015002303	Derivados de pirrolo[2,3-d]pirimidina

Supplementary Protection Certificates for CIBINQO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2958921	301155	Netherlands		PRODUCT NAME: ABROCITINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: PLGB 00057/1703-1705 20210908
2958921	PA2022502	Lithuania		PRODUCT NAME: ABROCITINIBAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/21/1593 20211209
2958921	CA 2022 00003	Denmark		PRODUCT NAME: ABROCITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1593 20211210
2958921	122022000007	Germany		PRODUCT NAME: ABROCITINIB, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1593 20211209
2958921	2022C/505	Belgium		PRODUCT NAME: ABROCITINIB, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/21/1593 20211210

CIBINQO Market Dynamics and Financial Trajectory: Abrocitinib Sales, Competition, Exclusivity and Growth Outlook

Last updated: August 2, 2026

CIBINQO, Pfizer’s oral JAK1 inhibitor abrocitinib, has established a commercial position in moderate-to-severe atopic dermatitis but remains materially smaller than Dupixent and Rinvoq. Its growth depends on oral-treatment demand, access to biologic-ineligible or biologic-reluctant patients, adolescent adoption, international expansion and differentiation against other JAK inhibitors. Pfizer’s reported CIBINQO revenue increased from approximately $79 million in 2022 to roughly $200 million in 2023 and approximately $300 million in 2024, based on company financial disclosures and reported product sales. The product remains commercially relevant, but its trajectory is constrained by boxed-warning safety language, intense competition and a later market entry than leading biologic therapies.[1-3]

What is CIBINQO and how does abrocitinib work?

CIBINQO is the branded formulation of abrocitinib, an oral, selective Janus kinase 1 inhibitor. It suppresses signaling from cytokines implicated in atopic dermatitis, including interleukin-4, interleukin-13, interleukin-31 and thymic stromal lymphopoietin.

The U.S. Food and Drug Administration approved CIBINQO in January 2022 for adults and adolescents aged 12 years and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic prescription therapies, including biologics, or when those therapies are not advisable.[4]

CIBINQO approved doses and treatment positioning

The principal U.S. doses are:

Dose	Typical positioning
100 mg once daily	Lower-dose treatment option
200 mg once daily	Higher-efficacy option for selected patients
50 mg or 100 mg once daily	Dose reduction in certain renal or drug-interaction settings

CIBINQO is generally positioned for patients who require systemic therapy and prefer an oral treatment. Its principal clinical alternatives include dupilumab, tralokinumab, lebrikizumab, upadacitinib and conventional immunosuppressants.

How large is the CIBINQO market?

Atopic dermatitis is a large chronic inflammatory disease market with substantial unmet need in moderate-to-severe patients. The market is shifting from older immunosuppressants toward targeted biologics and oral small molecules.

The commercial market has four major segments:

1. Biologic-naive patients starting systemic therapy.
2. Patients with inadequate response to biologic therapy.
3. Patients who prefer an oral medicine over an injection.
4. Patients requiring rapid itch and skin-clearance improvement.

CIBINQO competes most directly in the fourth and third segments. Oral JAK inhibitors can produce rapid clinical improvement, which supports prescribing in patients with severe pruritus or inadequate response to topical and biologic treatments. Their use is restricted by safety warnings and payer controls.

How does CIBINQO compare with leading atopic dermatitis drugs?

Product	Active ingredient	Manufacturer	Route	Core competitive position
CIBINQO	Abrocitinib	Pfizer	Oral	Selective JAK1 inhibitor with rapid symptom response
DUPIXENT	Dupilumab	Sanofi and Regeneron	Injection	Market-leading biologic with broad label and established safety profile
RINVOQ	Upadacitinib	AbbVie	Oral	Strong efficacy and major immunology commercial infrastructure
ADBRY	Tralokinumab	LEO Pharma	Injection	IL-13 biologic
EBGLYSS	Lebrikizumab	Eli Lilly and Almirall	Injection	IL-13 biologic with expanding market access
OLUMIANT	Baricitinib	Eli Lilly	Oral	JAK inhibitor with narrower atopic dermatitis commercial position in some markets

Dupixent has the strongest incumbent position because of its early entry, broad indications and extensive physician familiarity. Rinvoq is CIBINQO’s strongest oral competitor because AbbVie has major immunology sales capabilities and a broad JAK development platform.

What has been CIBINQO’s financial trajectory?

Pfizer’s reported CIBINQO sales have grown from a low launch base, but the product is not yet a major contributor to Pfizer’s consolidated revenue.

Year	Approximate CIBINQO revenue	Commercial interpretation
2022	$79 million	Partial first year after U.S. launch
2023	Approximately $200 million	Continued U.S. uptake and international contribution
2024	Approximately $300 million	Broader market penetration, though below leading competitors

Pfizer has not positioned CIBINQO as a replacement for its largest products. Its financial value is tied to growth in immunology and the company’s ability to build a durable post-launch franchise around JAK1 inhibition.

The revenue trajectory has several characteristics:

• The 2022 base was affected by the January launch and gradual payer coverage.
• 2023 growth reflected broader physician adoption and increased use in adolescents.
• 2024 growth benefited from expansion outside the initial U.S. launch cohort.
• Future growth is likely to moderate as competition increases and payer utilization management remains active.

CIBINQO’s revenue is commercially meaningful for Pfizer’s inflammation portfolio but remains small relative to products such as Eliquis, Vyndaqel, Prevnar and Ibrance.

What is the likely long-term sales ceiling?

CIBINQO has a credible path to annual sales in the several-hundred-million-dollar range. Reaching blockbuster status would require substantial share capture from Dupixent and Rinvoq, successful use after biologic failure, stronger adolescent adoption and label expansion.

The most important constraint is not disease prevalence. It is treatment sequencing. Many patients begin with topical therapy or a biologic, and physicians may reserve oral JAK inhibitors for patients with inadequate response, rapid symptom needs or a preference against injections.

What regulatory factors affect CIBINQO demand?

CIBINQO carries a boxed warning for serious infections, mortality, malignancies, major adverse cardiovascular events and thrombosis, reflecting the class-level risk profile associated with systemic JAK inhibitors.[4]

The label also includes warnings concerning:

• Serious infections, including tuberculosis and opportunistic infections.
• Herpes zoster.
• Laboratory abnormalities involving blood counts and lipids.
• Malignancy.
• Thrombosis.
• Cardiovascular events.
• Avoidance or limitation with certain immunosuppressive therapies.

These warnings influence prescribing, prior authorization and patient selection. They are particularly important when CIBINQO is compared with Dupixent, which does not carry the same JAK-class boxed warning.

How does FDA status affect the commercial outlook?

CIBINQO has full FDA approval in its labeled population, but the approval does not eliminate market-access friction. Payers may require:

• Failure of topical corticosteroids or calcineurin inhibitors.
• Prior treatment with a biologic.
• Documentation of moderate-to-severe disease.
• Specialist prescribing.
• Risk assessment for infection, cardiovascular disease and thrombosis.

The label supports adult and adolescent use, which broadens the addressable population. Pfizer’s commercial performance depends on converting that label into preferred formulary placement and routine use in treatment algorithms.

What patents protect CIBINQO and when does it lose exclusivity?

CIBINQO’s exclusivity is based on regulatory exclusivity, listed patents and Pfizer’s broader intellectual-property portfolio covering abrocitinib, pharmaceutical compositions, dosage forms and therapeutic use.

The core U.S. patent estate is expected to provide protection into the early 2030s, subject to patent-term adjustment, patent-term extension and the scope of Orange Book listings. The relevant protection categories include:

Protection category	Commercial purpose
Abrocitinib compound claims	Protect the active pharmaceutical ingredient
Pharmaceutical composition claims	Protect dosage-form and excipient combinations
Treatment-method claims	Protect use in atopic dermatitis and related inflammatory diseases
Dosing claims	Protect selected dose regimens and patient populations
Manufacturing claims	Protect processes for producing abrocitinib or intermediates

Exact generic-entry timing depends on the patents listed in the FDA Orange Book, any pediatric exclusivity, patent-term extension and the outcome of Paragraph IV litigation. Pfizer’s commercial risk is therefore more accurately assessed by patent family and claim scope than by a single nominal expiration date.[5]

Are there CIBINQO Paragraph IV challenges?

Public generic competition risk should be monitored through FDA ANDA filings, Orange Book certifications and federal patent litigation. A Paragraph IV certification would assert that a listed patent is invalid, unenforceable or not infringed.

No generic launch can occur before the applicable patent and regulatory barriers are resolved, unless the challenger prevails or reaches a settlement that permits an earlier entry. The timing of a first Paragraph IV filing is commercially important because the first qualifying challenger may receive 180 days of generic exclusivity under the Hatch-Waxman framework.

CIBINQO is a small-molecule drug, so its principal U.S. loss-of-exclusivity risk is generic substitution rather than biosimilar competition.

Is CIBINQO exposed to biosimilar risk?

CIBINQO has no conventional biosimilar risk because abrocitinib is a chemically synthesized small molecule. The relevant threat is an ANDA-based generic.

Its biologic competitors face a different framework. Dupixent, tralokinumab and lebrikizumab are biologics and may eventually face biosimilar or interchangeable-product competition, although the commercial impact depends on patent settlements, FDA approvals, payer substitution and physician behavior.

This distinction gives CIBINQO a potential advantage in manufacturing simplicity and eventual generic scalability. It also creates greater long-term substitution risk after small-molecule patent expiry.

Which companies are challenging CIBINQO commercially?

CIBINQO faces competition from multiple manufacturers rather than a single direct rival.

Dupixent: the incumbent benchmark

Sanofi and Regeneron’s Dupixent has the broadest commercial footprint in atopic dermatitis. Its advantages include extensive clinical use, a strong safety reputation relative to JAK inhibitors, multiple approved indications and high physician awareness.

CIBINQO’s counter-position is oral administration and rapid symptom control. Its limitation is the boxed warning and narrower franchise scale.

Rinvoq: the strongest oral competitor

AbbVie’s Rinvoq competes directly on oral convenience and efficacy. AbbVie’s immunology infrastructure, payer relationships and broader inflammatory-disease portfolio support aggressive commercial execution.

CIBINQO can compete where physicians favor selective JAK1 treatment or where patient-specific factors support abrocitinib. Rinvoq remains a major pressure on CIBINQO’s ability to expand oral-class share.

New biologics and IL-13 competition

Ebglyss and Adbry increase pressure on all established therapies. Their commercial value depends on efficacy, dosing convenience, injection burden, safety perception and formulary positioning.

The market is likely to remain segmented rather than dominated by one mechanism. Biologics will continue to attract patients prioritizing long-term safety and established treatment experience, while oral JAK inhibitors will retain demand among patients seeking rapid response and avoiding injections.

What manufacturing and intellectual-property barriers affect CIBINQO?

Abrocitinib is a synthetic small molecule and does not present the cell-line, comparability and biologic manufacturing issues associated with monoclonal antibodies. The main manufacturing barriers are:

• Control of active pharmaceutical ingredient purity.
• Process consistency and impurity management.
• Scale-up of chemical intermediates.
• Stability and finished-dose manufacturing.
• Regulatory qualification of alternative suppliers.

Manufacturing barriers support Pfizer’s near-term supply reliability but are unlikely to prevent eventual generic entry once core patents expire. Process patents can delay or complicate generic development if they cover commercially necessary routes, but formulation and method patents are generally more vulnerable to design-around strategies.

What licensing deals support CIBINQO?

CIBINQO originated from Pfizer’s internal small-molecule research and is marketed globally by Pfizer. Unlike several major immunology products, it is not primarily dependent on a high-profile external licensing transaction for commercial distribution.

Pfizer’s strategic advantage is its global infrastructure, regulatory organization and established specialty-care sales network. The limitation is portfolio prioritization: CIBINQO competes for investment against larger Pfizer franchises and other pipeline assets.

What generic launch scenarios exist for CIBINQO?

Three scenarios are commercially relevant:

Scenario	Expected effect
Patent-protected entry after early 2030s	Pfizer retains substantial branded revenue for longer
Authorized or negotiated early entry	Revenue declines before nominal patent expiry
Successful Paragraph IV challenge	Accelerated generic erosion and potential damages exposure

A standard small-molecule erosion pattern would likely produce rapid price and volume pressure after multiple generic entrants. The decline could be moderated if Pfizer maintains strong specialist loyalty, secures authorized-generic control or shifts patients to newer products. The underlying drug’s oral formulation makes generic substitution operationally easier than substitution involving injectable biologics.

How strong is the CIBINQO commercial and patent estate?

CIBINQO’s commercial estate is moderate rather than dominant.

Strengths include:

• Oral administration.
• Selective JAK1 mechanism.
• Rapid symptom-response profile.
• FDA approval for adolescents and adults.
• Pfizer’s global regulatory and commercial infrastructure.
• Potential use after inadequate biologic response.

Weaknesses include:

• Dupixent’s entrenched market leadership.
• Rinvoq’s direct oral competition.
• JAK-class boxed warning.
• Payer restrictions.
• Limited indication breadth relative to leading immunology franchises.
• Eventual ANDA substitution risk.

The patent estate is commercially valuable if core compound and composition claims remain enforceable into the early 2030s. Its effective strength will depend on Orange Book listing quality, claim breadth, patent-term adjustments and the outcome of any Paragraph IV proceedings.

Key Takeaways

• CIBINQO is Pfizer’s oral JAK1 inhibitor for moderate-to-severe atopic dermatitis.
• Reported sales increased from approximately $79 million in 2022 to roughly $200 million in 2023 and approximately $300 million in 2024.
• Dupixent is the principal biologic benchmark; Rinvoq is the strongest oral competitor.
• Growth depends on oral-treatment preference, rapid itch control, adolescent prescribing and use after biologic failure.
• The FDA boxed warning for systemic JAK inhibitors remains the product’s central commercial limitation.
• CIBINQO faces generic rather than biosimilar risk.
• Core patent protection is expected to extend into the early 2030s, subject to Orange Book status, patent-term adjustments and litigation.
• The product has a credible path to several-hundred-million-dollar annual sales but is unlikely to displace the leading atopic dermatitis franchises without meaningful label or market-access gains.

FAQs About CIBINQO Market and Financial Outlook

Does CIBINQO compete directly with Dupixent?

Yes. Both treat moderate-to-severe atopic dermatitis, but CIBINQO is an oral JAK1 inhibitor while Dupixent is an injectable biologic. CIBINQO competes on oral convenience and rapid response; Dupixent benefits from longer commercial experience and a more favorable safety perception.

Is CIBINQO a blockbuster drug?

No. CIBINQO’s reported annual sales remain below the conventional $1 billion blockbuster threshold. Its revenue trajectory is positive, but substantial growth is required to reach that level.

Can a generic version of CIBINQO be approved?

Yes. Because abrocitinib is a small molecule, generic manufacturers can pursue approval through the FDA ANDA pathway after addressing listed patents, regulatory exclusivity and any litigation.

What is the main risk to CIBINQO sales?

The main risk is competitive and regulatory pressure from Dupixent and Rinvoq, reinforced by the boxed warning applicable to systemic JAK inhibitors. Payer restrictions can amplify that pressure.

Does Pfizer have a biosimilar risk for CIBINQO?

No. CIBINQO is not a biologic. Its post-exclusivity exposure is to generic abrocitinib products, not biosimilars.

References

1. Pfizer Inc. (2023). 2022 annual report. Pfizer Investor Relations.
2. Pfizer Inc. (2024). 2023 annual report. Pfizer Investor Relations.
3. Pfizer Inc. (2025). 2024 annual report. Pfizer Investor Relations.
4. U.S. Food and Drug Administration. (2024). CIBINQO (abrocitinib) prescribing information.
5. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.

DrugChatter Q&A for CIBINQO

Cibinqo abrocitinib chemistry manufacturing process patent?
Cibinqo fda approval date?
Fda cibinqo abrocitinib chemistry manufacturing synthesis patent?
Cibinqo for atopic eczema?
Cibinqo atopic dermatitis?